Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis

被引：40
作者：
Cottrell, Mackenzie L. [1 ]
Prince, Heather M. A. [2 ]
Schauer, Amanda P. [1 ]
Sykes, Craig [1 ]
Maffuid, Kaitlyn [1 ]
Poliseno, Amanda [1 ]
Chun, Tae-Wook [3 ]
Huiting, Erin [3 ]
Stanczyk, Frank Z. [4 ]
Peery, Anne F. [5 ]
Dellon, Evan S. [5 ]
Adams, Jessica L. [6 ,7 ]
Gay, Cindy [2 ]
Kashuba, Angela D. M. [1 ,2 ]
机构：
[1] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Div Infect Dis, Sch Med, Chapel Hill, NC 27515 USA
[3] NIAID, HIV Immunovirol Unit, 9000 Rockville Pike, Bethesda, MD 20892 USA
[4] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[5] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA
[6] Univ Sci, Philadelphia Coll Pharm, Philadelphia, PA USA
[7] Cooper Univ Hosp, Early Intervent Program, Camden, NJ USA
来源：
CLINICAL INFECTIOUS DISEASES | 2019年 / 69卷 / 12期
基金：
美国国家卫生研究院;
关键词：
transgender; preexposure prophylaxis; lower gastrointestinal tract; HIV; feminizing hormone therapy; HIV; WOMEN; NUCLEOTIDE;
D O I：
10.1093/cid/ciz290
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP's active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (rho = -0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy.
引用
收藏
页码：2201 / 2204
页数：4
相关论文
共 15 条
  • [1] Worldwide burden of HIV in transgender women: a systematic review and meta-analysis
    Baral, Stefan D.
    Poteat, Tonia
    Stromdahl, Susanne
    Wirtz, Andrea L.
    Guadamuz, Thomas E.
    Beyrer, Chris
    [J]. LANCET INFECTIOUS DISEASES, 2013, 13 (03) : 214 - 222
  • [2] FEM-PrEP: Adherence Patterns and Factors Associated With Adherence to a Daily Oral Study Product for Pre-exposure Prophylaxis
    Corneli, Amy L.
    Deese, Jennifer
    Wang, Meng
    Taylor, Doug
    Ahmed, Khatija
    Agot, Kawango
    Lombaard, Johan
    Manongi, Rachel
    Kapiga, Saidi
    Kashuba, Angela
    Van Damme, Lut
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 66 (03) : 324 - 331
  • [3] A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine
    Cottrell, Mackenzie L.
    Yang, Kuo H.
    Prince, Heather M. A.
    Sykes, Craig
    White, Nicole
    Malone, Stephanie
    Dellon, Evan S.
    Madanick, Ryan D.
    Shaheen, Nicholas J.
    Hudgens, Michael G.
    Wulff, Jacob
    Patterson, Kristine B.
    Nelson, Julie A. E.
    Kashuba, Angela D. M.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2016, 214 (01) : 55 - 64
  • [4] Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir
    Das, Biswajit
    Dobrowolski, Curtis
    Luttge, Benjamin
    Valadkhan, Saba
    Chomont, Nicolas
    Johnston, Rowena
    Bacchetti, Peter
    Hoh, Rebecca
    Gandhi, Monica
    Deeks, Steven G.
    Scully, Eileen
    Karn, Jonathan
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (33) : E7795 - E7804
  • [5] HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial
    Deutsch, Madeline B.
    Glidden, David V.
    Sevelius, Jae
    Keatley, Joanne
    McMahan, Vanessa
    Guanira, Juan
    Kallas, Esper G.
    Chariyalertsak, Suwat
    Grant, Robert M.
    [J]. LANCET HIV, 2015, 2 (12): : E512 - E519
  • [6] Effects of Cross-Sex Hormone Treatment on Transgender Women and Men
    Deutsch, Madeline B.
    Bhakri, Vipra
    Kubicek, Katrina
    [J]. OBSTETRICS AND GYNECOLOGY, 2015, 125 (03) : 605 - 610
  • [7] Natural Substrate Concentrations Can Modulate the Prophylactic Efficacy of Nucleotide HIV Reverse Transcriptase Inhibitors
    Garcia-Lerma, J. Gerardo
    Aung, Wutyi
    Cong, Mian-er
    Zheng, Qi
    Youngpairoj, Ae S.
    Mitchell, James
    Holder, Angela
    Martin, Amy
    Kuklenyik, Susan
    Luo, Wei
    Lin, Carol Yen-Chin
    Hanson, Debra L.
    Kersh, Ellen
    Pau, Chou-Pong
    Ray, Adrian S.
    Rooney, James F.
    Lee, William A.
    Heneine, Walid
    [J]. JOURNAL OF VIROLOGY, 2011, 85 (13) : 6610 - 6617
  • [8] Hiransuthikul A, 2018, AIDS2018
  • [9] The 5′-nucleotidases as regulators of nucleotide and drug metabolism
    Hunsucker, SA
    Mitchell, BS
    Spychala, J
    [J]. PHARMACOLOGY & THERAPEUTICS, 2005, 107 (01) : 1 - 30
  • [10] Specific Inhibition of HIV Infection by the Action of Spironolactone in T Cells
    Lacombe, Benoit
    Morel, Marina
    Margottin-Goguet, Florence
    Ramirez, Bertha Cecilia
    [J]. JOURNAL OF VIROLOGY, 2016, 90 (23) : 10972 - 10980
12